Augmented depression therapy shows potential as effective, cost-efficient depression care
A promising new approach in depression care, termed augmented depression therapy (ADepT), has demonstrated promising results in a pilot study from the University of Exeter, potentially outperforming the current standard treatment, cognitive behavioral therapy (CBT).
Key Points:
- Augmented depression therapy (ADepT) has demonstrated encouraging preliminary signs of efficacy, surpassing cognitive behavioral therapy (CBT) in certain aspects.
- ADepT focuses equally on reducing depressive symptoms and fostering well-being, effectively targeting anhedonia, a core component of depression often missed by current therapies.
- 82 adults with moderate to severe depression participated in the pilot trial, and results suggested ADepT was at least as effective as CBT, if not better, at promoting well-being and reducing depressive symptoms.
- Economic analysis indicated ADepT to be as cost-effective as CBT while delivering better quality of life outcomes.
Additional Points:
- The trial was spearheaded by Professor Barney Dunn, a Clinical Psychology professor at the University of Exeter.
- Participants in the study were primarily selected from NHS Talking Therapy service waiting lists in Devon, UK.
- ADefT was developed to be seamlessly incorporated into the current therapeutic framework, requiring minimal additional training for existing CBT therapists.
Conclusion:
- If validated in subsequent trials, ADepT may offer both clinical and economic advantages over current therapeutic modalities in depression treatment, marking a significant advancement in mental health care.
Psychiatry Latest Posts